×

Akers Biosciences Signs Agreement to Sell METRON(R) Breath Ketone Test Online, With Key Focus on Amazon Marketplace

THOROFARE, N.J., May 6, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, has appointed InstaNatural, LLC., (the "Reseller") as its online marketing partner to build consumer awareness and preference, with exclusive rights for Amazon representation, for the Company's consumer-focused METRON® breath ketone test, aimed at the health and wellness market.

The METRON® breath ketone test is the only disposable breath-based diagnostic device that rapidly determines if the subject is in the optimal fat-burning state for weight loss, known as ketosis. Achieving a state of ketosis is a goal of many individuals following low carbohydrate diets. METRON®, based on the Company's proprietary MPC Biosensor technology, uses a simple, non-invasive process to identify in minutes whether ketones present in exhaled breath are at a level indicative of ketosis.

"Ketosis is a state at which the body has an extremely high fat-burning rate," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of the Board. "It is therefore an essential metabolic state for endurance athletes and anybody who is serious about losing weight."

"We have seen significant consumer interest in the METRON® breath ketone test since the Company announced its development because of its simplicity and accuracy when compared to existing urine or blood-based tests. We are very excited to be making it available later this year online, with a focus on Amazon, which is the largest U.S. online retailer," continued Dr. Akers. "Our strategic partners are experts in online product positioning and new product launches and will be initially targeting the weight-loss market, as well as endurance athletes."

"It is an honor to be chosen by Akers Bio to bring their proprietary, game-changing diagnostic to the online consumer," Aditya Patel, President of InstaNatural, LLC added. "We are enthusiastic about the potential of this partnership and for the power it brings to improve the health and wellness of consumers following ketogenic (low-carb) diets."

The Reseller intends to employ dedicated and specially trained personnel to promote online sales and to support the growth of the customer base.

The Agreement will automatically renew for one year at each anniversary, provided the Reseller achieves certain contractual milestones.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbiosciences.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

CONTACT: For more information: Akers Biosciences, Inc. Raymond F. Akers, Jr. PhD Executive Chairman of the Board Tel. +1 856 848 8698 finnCap (UK Nominated Adviser and Broker) Geoff Nash / Scott Mathieson (Corporate Finance) Steve Norcross (Broking) Tel. +44 (0) 20 7220 0500 Taglich Brothers, Inc. (US Investor Relations) Chris Schreiber Tel. +1 917 445 6207 Vigo Communications (UK Investor Relations) Ben Simons / Fiona Henson Tel. +44 (0) 20 7016 9570 Email: akers@vigocomms.com

Source:Akers Biosciences, Inc.